PEPTIDE GUIDE

What Is Cagrilintide?

Cagrilintide is an investigational peptide designed to copy some of the actions of amylin, a natural hormone released by the pancreas after food is eaten. It is being studied for weight management, both on its own and with semaglutide.

Novo Nordisk A/S, a Danish pharmaceutical company that develops medicines for diabetes and other chronic conditions, developed cagrilintide under the code AM833. It has reached Phase 3 trials, the large studies normally used to confirm benefit and gather broader safety evidence before regulatory review. It is not currently an approved medicine on its own.

Research statusInvestigational medicine with Phase 3 human evidence
Development codeAM833
Peptide typeThirty-seven-amino-acid long-acting amylin analogue
Human evidencePhase 3 clinical trials
Last reviewed2 November 2026
THE SHORT ANSWER

Cagrilintide is a 37-amino-acid, long-acting version of the hormone amylin. It is intended to strengthen signals of fullness and reduce food intake. A 26-week Phase 2 trial found average weight reductions of about 6.0% to 10.8% across the cagrilintide groups, compared with 3.0% for placebo. In REDEFINE 1, a 68-week Phase 3 trial in adults with obesity, or overweight with a related health condition, but not diabetes, cagrilintide alone produced an estimated 11.5% average reduction, compared with 3.0% for placebo. The combination of cagrilintide and semaglutide, called CagriSema, produced larger average reductions, but those results do not show what cagrilintide would achieve alone. Digestive side effects were common. Cagrilintide remains investigational and no unapproved product should be presented as the trial medicine.

What is amylin?

Amylin is a peptide hormone made by beta cells in the pancreas. Beta cells also make insulin, the hormone that helps move glucose from the blood into cells. Glucose is the main sugar used by the body for energy.

Amylin is released alongside insulin after eating. It helps limit meal size by signalling satiation, the feeling that causes a person to stop eating during a meal. It can also slow gastric emptying, meaning food leaves the stomach more slowly, and can reduce the release of glucagon after meals. Glucagon is a hormone that tells the liver to release stored glucose.

Natural human amylin contains 37 amino acids. It tends to form clumps called amyloid fibrils, which makes the natural molecule difficult to turn into a stable medicine. Researchers therefore make analogues. An analogue is a designed molecule that resembles a natural one but has changes intended to improve its behaviour as a medicine.

Pramlintide is an earlier amylin analogue approved in the United States as an additional treatment for some people using mealtime insulin. Its approval and safety record do not transfer to cagrilintide, which is a different molecule under separate investigation.

What is cagrilintide made from?

Cagrilintide is a synthetic 37-amino-acid peptide based on human amylin. Novo Nordisk researchers changed selected amino acids to reduce clumping and improve stability. They also attached a fatty-acid side chain through a chemical linker.

The fatty-acid side chain can bind reversibly to albumin, the most abundant protein in blood. Reversible means the peptide can attach and later detach. Albumin binding helps protect the peptide from rapid removal and supports a longer period in the circulation.

Cagrilintide also retains a small internal bridge between two cysteine residues near the beginning of the chain. Cysteine is an amino acid that contains sulphur. Two cysteines can form a disulphide bond, which helps hold part of the peptide in its intended shape.

These changes make cagrilintide more than purified human amylin. Findings about the body's natural hormone cannot automatically be used to predict the exact benefits or risks of its long-acting analogue.

When was cagrilintide first documented?

The scientific route to cagrilintide began decades before the molecule itself. Human amylin was identified in the 1980s in deposits found in the pancreatic islets of people with type 2 diabetes. Pancreatic islets are small groups of hormone-making cells in the pancreas.

Novo Nordisk later designed a group of stable, lipidated amylin analogues. Lipidated means that a fatty-acid side chain has been attached. The company selected the candidate known as compound 23 or AM833 for clinical development and named it cagrilintide.

The first prominent peer-reviewed paper setting out the molecule's design and selection was published in 2021. Clinical research was already under way by then. The Phase 1b combination study and Phase 2 monotherapy study were also published in 2021. Phase 1 studies provide the first structured assessment of safety and how the body handles a medicine. A “1b” study is a later early-stage trial, often involving people closer to the intended treatment population.

Phase 3 results for CagriSema appeared in 2025. Novo Nordisk reported that it submitted CagriSema for US regulatory review in December 2025. A submission is a request for review, not an approval, and it concerns the combination product rather than cagrilintide alone.

Year or timeframeDevelopment milestone
1980sHuman amylin was identified and its role began to be characterised
2010sNovo Nordisk designed and selected the long-acting candidate AM833
2021Development, Phase 1b combination and Phase 2 monotherapy papers were published
2023Phase 2 CagriSema results in type 2 diabetes were published
2025REDEFINE 1 and REDEFINE 2 Phase 3 results were published
December 2025Novo Nordisk submitted CagriSema for FDA review in weight management
June to August 2026Three REIMAGINE Phase 3 diabetes trials were published
September 2026Novo Nordisk reported initial REIMAGINE 5 and REDEFINE 9 results; full peer-reviewed reports were not yet available

How is cagrilintide synthesised and manufactured?

Cagrilintide is made by chemical peptide synthesis rather than extracted from a human or animal pancreas. Its length and modifications make manufacture more involved than for a short, unmodified peptide.

The main raw materials are protected amino-acid building blocks corresponding to the 37 positions in the designed sequence. They include protected cysteine building blocks for the disulphide bridge. Manufacture also requires a solid resin, coupling chemicals, temporary protecting groups and solvents used during peptide assembly. A fatty-acid building block and a linker material are needed for lipidation.

In solid-phase peptide synthesis, or SPPS, the first protected amino acid is attached to insoluble resin beads. The chain is built one amino acid at a time. At each stage, a temporary group is removed and the next building block is joined through a peptide bond. A peptide bond is the chemical link between neighbouring amino acids.

The lipid side chain is attached at its selected position. After the full sequence has been assembled, the peptide is removed from the resin and its remaining protecting groups are taken off. Controlled oxidation allows the two selected cysteines to form the internal disulphide bond. Oxidation here describes the chemical step that links their sulphur atoms.

The crude peptide is then purified, commonly with preparative high-performance liquid chromatography, shortened to HPLC. HPLC separates molecules according to how they interact with a column. Mass spectrometry checks molecular mass, and analytical HPLC estimates purity. Further tests may examine the correct disulphide bond, lipid attachment, water content, residual solvents and breakdown products.

A medicine for clinical use requires validated manufacture, sterile formulation, checks for microorganisms and bacterial toxins, and evidence that batches remain within limits over time. A peptide sold online with a purity figure has not necessarily met these wider controls or matched the cagrilintide used in trials.

This overview is educational. It does not give a laboratory recipe, quantities, temperatures, reaction times, equipment settings, sterile filling method or instructions for preparing a product for administration.

How does cagrilintide work?

Cagrilintide activates amylin receptors. These receptors are assembled from a calcitonin receptor and one of several receptor-activity-modifying proteins. The technical construction matters to scientists because it produces more than one amylin receptor type. For a general reader, the central point is that cagrilintide copies a signal involved in meal size and fullness.

Important receptor sites are found in the hindbrain, including the area postrema. The hindbrain helps coordinate basic functions and receives chemical information from the blood. The area postrema is involved in appetite signals but also in nausea and vomiting, which helps explain why digestive side effects appear in trials.

Cagrilintide may also affect food reward, meaning how strongly the brain values and seeks food, as well as the physical signal to stop a meal. A proposed mechanism is not the same as a measured clinical outcome. Weight change in randomised human trials remains more informative than receptor or animal findings alone.

How are amylin receptors constructed?

Amylin receptors are not single proteins working alone. A calcitonin receptor forms the core and joins one of three receptor-activity-modifying proteins, usually shortened to RAMPs. The RAMP changes how the completed receptor recognises signals and where it is found in the body.

This produces several receptor forms rather than one universal amylin switch. Cagrilintide can activate amylin receptors and also has activity at the calcitonin receptor. Calcitonin is a hormone involved in calcium regulation, although the relevance of direct calcitonin-receptor activity to cagrilintide's weight effects is not fully settled.

Receptor activation starts signalling inside the cell. In brain regions involved in appetite, the overall effect is thought to strengthen satiation and reduce energy intake. Satiation is the process that brings an individual meal to an end. Satiety is the feeling of fullness that continues after the meal. The terms are related but not identical.

Animal studies and early human measurements can help locate these signals, but the mechanism does not predict the percentage of weight change a person will experience. It also cannot show whether a long-term health outcome, such as fewer heart attacks, will improve.

Is cagrilintide a GLP-1 medicine?

No. Cagrilintide is an amylin analogue. Semaglutide is an analogue of glucagon-like peptide 1, normally shortened to GLP-1. GLP-1 is a gut hormone that supports insulin release when glucose is high, reduces glucagon, slows gastric emptying and influences appetite.

The two pathways overlap in their effects on eating, but they use different receptors. This is the reason researchers have tested the molecules together. It does not mean that cagrilintide and semaglutide are the same medicine.

What is CagriSema?

CagriSema is the development name for co-administered cagrilintide and semaglutide. Co-administered means the two medicines are given as part of the same treatment programme.

Results for CagriSema measure the combined approach. They cannot reveal how much of the effect came from cagrilintide, how much came from semaglutide or whether the interaction would be identical with another medicine. They also do not support untested combinations with tirzepatide, retatrutide or other peptides.

This guide reports CagriSema research because it forms a large part of cagrilintide's human evidence. It does not recommend combining products.

What did the first combination study find?

The Phase 1b trial included 95 adults with overweight or obesity and lasted 20 weeks. Participants received semaglutide alongside different cagrilintide levels or semaglutide alongside placebo. Placebo is an inactive comparison designed to resemble the study treatment.

The study used gradual increases in the research administration levels to assess tolerability. Weight reduction was larger in several combination groups than with semaglutide alone, reaching about 15.4% in the group receiving 2.4 milligrams of each component and 17.1% in the group receiving cagrilintide 4.5 milligrams with semaglutide 2.4 milligrams. The semaglutide plus placebo group lost about 9.8% on average.

The group sizes were small because this was an early-stage study. Its purpose was to assess safety, tolerability, how the body handled the medicines and an early signal of effect. It was not large enough to define uncommon harms or confirm long-term outcomes.

The administration levels are part of the published trial context, not recommendations.

What did the Phase 2 cagrilintide-only trial find?

The Phase 2 study took place at 57 sites and included 706 adults with overweight or obesity in the cagrilintide groups, 99 in a liraglutide group and 101 receiving placebo. Liraglutide is an approved GLP-1 receptor medicine and served as an active comparison. An active comparison is an existing treatment rather than an inactive placebo.

Participants were randomly assigned to five cagrilintide levels ranging from 0.3 to 4.5 milligrams once weekly, daily liraglutide 3.0 milligrams, or placebo. Random assignment means chance determined the group. The trial was double-blind for cagrilintide and placebo, meaning participants and study staff did not know those assignments. Liraglutide could not be fully masked because its schedule differed.

After 26 weeks, average weight reductions were about 6.0%, 6.8%, 9.1%, 9.7% and 10.8% across increasing cagrilintide groups. The placebo group lost about 3.0% and the liraglutide group about 9.0%.

Weight change was the main outcome. The study was not designed to show that cagrilintide prevents heart attacks, strokes or early death. Those health outcomes require longer and often larger trials.

How should the Phase 2 result be interpreted?

The study shows a dose-response pattern, meaning larger average weight changes generally appeared across higher assigned cagrilintide levels. It also included both an inactive placebo and an active medicine comparison, which helps place the result in context.

It did not prove that cagrilintide was superior to liraglutide for every level or outcome. The trial was designed primarily to compare cagrilintide groups with placebo. Liraglutide also had a daily schedule while cagrilintide and placebo were weekly, so the active comparison could not be concealed in exactly the same way.

At least 5% weight reduction was reached by 53.5% to 76.4% of participants across the cagrilintide groups, compared with 30.9% receiving placebo. At least 10% was reached by 18.7% to 54.4% and 10.3%, respectively. These responder figures show that an average does not describe everyone. Some participants lost substantially more, while others did not reach the threshold.

The trial lasted 26 weeks. It could not answer whether weight change would continue, plateau or reverse later, and it was not long enough to define uncommon harms. The later Phase 3 programme was needed partly because a promising Phase 2 result is not enough for regulatory approval.

Gastrointestinal adverse events were the most common and occurred more often with cagrilintide than placebo. The study described most as mild or moderate. This wording refers to severity, not frequency or personal acceptability.

What did REDEFINE 1 find?

REDEFINE 1 was a 68-week Phase 3 trial in 3,417 adults without diabetes who had obesity, or overweight with at least one related health problem. Participants were randomly assigned to CagriSema, semaglutide alone, cagrilintide alone or placebo. All groups also received lifestyle support.

The estimated average weight change was a reduction of 20.4% with CagriSema, 14.9% with semaglutide, 11.5% with cagrilintide and 3.0% with placebo. This analysis counted outcomes regardless of whether every participant remained on the assigned product, which gives a practical estimate of what happened across the trial population.

The cagrilintide-only result is important because it comes from a large Phase 3 population. It was one arm within a combination trial, however, and the company subsequently began a separate programme intended to assess cagrilintide on its own.

Digestive adverse events were common across the active-treatment groups. The trial lasted long enough to measure substantial weight change, but it does not establish lifetime safety or what happens after treatment ends.

Why are two different REDEFINE 1 percentages reported?

Reports of REDEFINE 1 often quote either 20.4% or 22.7% average weight reduction for CagriSema. Both came from the same trial, but they answer different questions.

The treatment-policy analysis estimated what happened across all randomised participants regardless of whether they remained on the study product or used another weight-management treatment. It produced the 20.4% figure for CagriSema, 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo.

The efficacy analysis estimated the effect if participants remained on the assigned product as planned. It produced 22.7% for CagriSema, 16.1% for semaglutide, 11.8% for cagrilintide and 2.3% for placebo.

An estimand is the precise treatment effect a trial is designed to estimate. It defines the population, outcome and how events such as stopping treatment are handled. Neither analysis is automatically fraudulent or superior. The practical analysis may better reflect interruptions in real care, while the on-treatment analysis better describes the biological effect under continued trial use.

Using the larger percentage without explaining the analysis makes the treatment appear simpler and more certain than the data allow. It is also incorrect to present 22.7% as the cagrilintide-only result. That figure belongs to the combination.

What did REDEFINE 2 find?

REDEFINE 2 tested CagriSema rather than cagrilintide alone. It included 1,206 adults with type 2 diabetes and overweight or obesity across 12 countries. Participants were assigned in a three-to-one ratio to CagriSema or placebo for 68 weeks, alongside lifestyle support.

Type 2 diabetes is a condition in which blood glucose remains too high because the body does not use insulin effectively and may not produce enough. The study required a glycated haemoglobin, or HbA1c, of 7% to 10%. HbA1c estimates average blood-glucose exposure over roughly the previous two to three months.

Average weight fell by an estimated 13.7% with CagriSema and 3.4% with placebo. An HbA1c level of 6.5% or lower was reached by 73.5% of the CagriSema group and 15.9% of the placebo group. Digestive adverse events were reported by 72.5% and 34.4%, respectively, and most were described as temporary and mild or moderate.

These results show what happened with the combination in people with type 2 diabetes. They are not a cagrilintide-only result.

What has the REIMAGINE diabetes programme added?

REDEFINE studies focus mainly on weight management. REIMAGINE is a separate Phase 3 programme studying CagriSema in people with type 2 diabetes. It is evidence for the combination, not for cagrilintide alone.

REIMAGINE 1 included 189 adults whose diabetes was not adequately controlled by diet and exercise. After 40 weeks, average HbA1c fell by 1.8 percentage points with the higher-level CagriSema group and 1.5 points with the lower-level group, compared with 0.1 points with placebo. Average body weight fell by 13.8%, 11.8% and 1.4%, respectively.

REIMAGINE 2 included 2,713 adults taking metformin, with or without a sodium-glucose cotransporter-2 inhibitor. Metformin is a long-established type 2 diabetes medicine that reduces glucose production by the liver and improves the body's response to insulin. Sodium-glucose cotransporter-2 inhibitors, shortened to SGLT2 inhibitors, lower blood glucose by increasing the amount removed in urine.

The main comparison in REIMAGINE 2 was CagriSema 2.4 milligrams of each component against semaglutide 2.4 milligrams. After 68 weeks, HbA1c fell by an estimated 1.91 percentage points with CagriSema and 1.75 points with semaglutide. The difference was statistically significant but numerically modest at 0.16 percentage points. This is why statistical significance and size of benefit should be reported together.

REIMAGINE 3 included 274 adults already using basal insulin, with or without metformin. Basal insulin is a long-acting insulin used to control glucose between meals and overnight. At 40 weeks, HbA1c fell by 2.33 percentage points in the higher CagriSema group, 2.10 points in the lower group and 0.66 points with placebo. The active groups lost about 10% to 12% of body weight. No severe hypoglycaemia was reported. Hypoglycaemia means blood glucose has fallen too low.

These trials widen the diabetes evidence across early disease, oral medicines and basal insulin. They still do not establish prevention of complications such as kidney failure, sight loss, heart attack or stroke.

What was reported in September 2026?

On 21 September 2026, Novo Nordisk announced initial results from REIMAGINE 5 and REDEFINE 9. These were results released by the study sponsor before full peer-reviewed papers were available.

REIMAGINE 5 compared CagriSema 1.0 milligram of each component with tirzepatide 5 milligrams in adults with type 2 diabetes using metformin, an SGLT2 inhibitor or both. At week 60, the company reported average weight reductions of 12.4% and 9.1%. HbA1c fell by 1.71 and 1.67 percentage points. The trial concluded that the HbA1c reduction was non-inferior, meaning it was not worse than tirzepatide by more than a margin set in advance.

This does not show that CagriSema is better than every tirzepatide treatment level. It compared one specified level of each treatment under a particular trial protocol. It also cannot replace the detailed publication needed to examine withdrawals, missing data, adverse events and all prespecified outcomes.

REDEFINE 9 compared two CagriSema levels with placebo in adults with overweight or obesity. The company reported 21.0% average weight reduction with the 1.0 milligram combination and 2.0% with placebo at 68 weeks. Again, the result is informative but remains a sponsor report until the complete methods and analyses are published.

The same announcement stated that the FDA decision on the weight-management application was expected in the fourth quarter of 2026. As of 2 November 2026, CagriSema remains investigational in the United States. Novo Nordisk repeated its expectation of a fourth-quarter FDA decision on 20 October; an expected decision window is not an approval date.

Is cagrilintide still being studied on its own?

Yes. The cagrilintide-only arm in REDEFINE 1 produced an 11.5% average weight reduction in the treatment-policy analysis. Novo Nordisk has moved cagrilintide monotherapy into a separate Phase 3 programme called RENEW.

This matters because CagriSema results cannot answer every question about cagrilintide alone. A monotherapy programme can define its effect, tolerability and suitable comparison without semaglutide contributing to both benefit and adverse events.

Until those trials report, the strongest cagrilintide-only evidence remains the 26-week Phase 2 study and the monotherapy arm of REDEFINE 1. Starting Phase 3 does not establish a successful result.

What side effects have trials reported?

The most common adverse events have involved the digestive system, particularly nausea, vomiting, diarrhoea, constipation and abdominal discomfort. An adverse event is any unwanted medical occurrence during a study, whether or not researchers conclude that the medicine caused it.

Digestive effects are biologically plausible because amylin signalling affects satiation, gastric emptying and brain regions involved in nausea. They often appeared while research levels were being increased and were usually described as mild or moderate, but some participants stopped treatment.

Trials also monitor gallbladder disease, pancreatitis, low blood glucose and changes in pulse. Pancreatitis is inflammation of the pancreas. Low blood glucose is called hypoglycaemia. The risk of hypoglycaemia can depend on other diabetes medicines because amylin analogues do not act in isolation.

Cagrilintide's long-term and uncommon risks are not yet as fully characterised as those of an approved medicine with years of wider use. Safety findings for the CagriSema combination cannot always identify which component caused an event.

In REDEFINE 1, gastrointestinal events were reported by 79.6% of participants assigned to CagriSema and 39.9% receiving placebo. The active monotherapy groups also had more digestive events than placebo. Numbers from one trial should not be used to predict an individual's experience, but they show that “generally mild or moderate” does not mean uncommon.

REIMAGINE 2 reported any adverse event in 86.9% of the higher-level CagriSema group, 81.2% with semaglutide at the corresponding level, 82.2% with cagrilintide and 70.5% with placebo. Most common events in the active groups were gastrointestinal.

Trials use planned increases in administration level partly to improve tolerability. This guide reports final trial levels and outcomes as research context. It does not reproduce escalation schedules or turn them into personal instructions.

Has cardiovascular benefit been established?

No cardiovascular outcome benefit has yet been established for cagrilintide or CagriSema.

REDEFINE 1 later showed reductions in blood pressure and several metabolic measurements. Systolic blood pressure, the top number in a reading, fell by an average of 10.9 millimetres of mercury with CagriSema and 2.1 with placebo. A biomarker or risk-factor improvement is useful, but it is not the same as showing fewer heart attacks, strokes or cardiovascular deaths.

REDEFINE 3 is a dedicated cardiovascular-outcomes trial planned for about 7,000 adults with established cardiovascular disease and overweight or obesity. An event-driven trial continues until a prespecified number of clinical events has occurred. That design provides enough information to compare actual outcomes rather than relying only on risk markers.

Until that trial reports, cardiovascular claims must remain limited to measured changes such as weight, blood pressure and glucose. The proven cardiovascular benefits of approved semaglutide products cannot simply be transferred to an investigational combination.

Is cagrilintide approved?

Cagrilintide remains an investigational medicine. Investigational means it is being formally studied but has not received marketing authorisation for routine medical use.

Novo Nordisk reported submitting CagriSema to the FDA for weight management in December 2025. In September 2026, the company said a decision was expected during the fourth quarter of 2026. Regulatory review does not make a product approved, and the application concerns the cagrilintide-semaglutide combination. A European Medicines Agency paediatric investigation plan also does not amount to marketing authorisation. Such a plan sets out how a medicine may be studied in children during development.

There is no approved cagrilintide-only medicine. Products sold online as cagrilintide do not become trial products or approved medicines because they use the same name.

What does FDA say about cagrilintide compounding?

FDA states that cagrilintide cannot be used in compounding under US federal law. It is not a component of an FDA-approved drug. This statement concerns US law and should not be extended automatically to other countries.

The pending CagriSema application concerns a defined combination product. It neither authorises a cagrilintide-only product nor establishes that an online mixture reproduces the trial formulation. Any future approval would need to be described by the exact product, indication and jurisdiction.

What important questions remain unanswered?

The programme has measured weight and glucose over periods up to about 68 weeks. It has not yet defined the balance of benefit and harm over many years, what happens after long-term discontinuation, or the frequency of very uncommon adverse events.

Body composition also matters. Weight loss can include fat and lean tissue. Lean tissue includes muscle, organs, water and other non-fat components. A lower number on the scale does not by itself show how much came from visceral fat, fat beneath the skin or lean mass.

The published trials do not establish that cagrilintide prevents every obesity-related complication. They also do not show that a product from an online seller has the identity, formulation, stability or sterility of the trial medicine.

People with severe organ impairment, pregnancy, certain gastrointestinal conditions or medicines that affect glucose may be excluded or underrepresented in trials. An approved label would set out the regulator's conclusions for defined populations. Until then, gaps should not be filled with assumptions based on other amylin or GLP-1 medicines.

What benefits are claimed, and what does the evidence support?

ClaimWhat the evidence supports
Produces weight lossRandomised Phase 2 and Phase 3 studies show average weight reduction in studied populations
Works better with semaglutideCombination trials show larger average effects than cagrilintide alone, but also test a different treatment and safety profile
Treats type 2 diabetesCombination research improved HbA1c, but cagrilintide alone is not an approved diabetes medicine
Prevents heart attacks or strokesThis has not been established by the weight-management trials discussed here
Is an approved alternative to GLP-1 medicinesNo. Cagrilintide remains investigational and acts through amylin receptors
Can be combined with any weight-loss peptideNo adequate trial supports arbitrary combinations, and this guide provides no stacking advice
FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is cagrilintide a peptide?

Yes. It is a synthetic 37-amino-acid peptide based on the hormone amylin.

Is cagrilintide the same as semaglutide?

No. Cagrilintide is an amylin analogue and semaglutide is a GLP-1 analogue. They act through different receptors.

What is CagriSema?

CagriSema is the development name for cagrilintide and semaglutide used together in a clinical programme.

Is cagrilintide approved by the FDA?

No cagrilintide-only medicine is FDA approved. Submission of CagriSema for review is not the same as approval.

How much weight did people lose with cagrilintide alone?

Average reductions ranged from about 6.0% to 10.8% across groups in a 26-week Phase 2 trial. In REDEFINE 1, the estimated average reduction with cagrilintide alone was 11.5% at 68 weeks, compared with 3.0% for placebo.

What were the cagrilintide administration levels in trials?

The Phase 2 study compared weekly levels from 0.3 to 4.5 milligrams. REDEFINE 1 used a target level of 2.4 milligrams. These are documented research conditions, not personal dosing guidance.

What are the common side effects?

Nausea, vomiting, diarrhoea, constipation and abdominal discomfort have been commonly reported across cagrilintide and CagriSema studies.

How is cagrilintide made?

It is assembled chemically from protected amino acids, fitted with a fatty-acid side chain, folded to form an internal disulphide bridge, purified and tested.

When was cagrilintide first documented?

Clinical development began in the late 2010s, and the main peer-reviewed paper describing the molecule's design was published in 2021.

Is cagrilintide an insulin?

No. It is an analogue of amylin, a separate hormone that is normally released alongside insulin.

Can cagrilintide be combined with tirzepatide or retatrutide?

This guide provides no combination or stacking advice. Results for CagriSema cannot be transferred to different combinations.

What the evidence supports today

Cagrilintide has moved beyond cell and animal research. Randomised Phase 2 trials and a large Phase 3 trial show clinically meaningful average weight reduction when it is used alone. The CagriSema programme also shows substantial effects with semaglutide in people with and without type 2 diabetes.

Several limits remain important. Combination results are not cagrilintide-only results. Weight reduction does not automatically establish prevention of cardiovascular disease or long-term safety. Digestive side effects are common, and uncommon risks take time and larger exposure to define. The Research Methodology guide explains how Orentra Labs assesses these evidence limits.

The current description is therefore straightforward: cagrilintide is a long-acting amylin analogue with substantial human trial evidence, but it remains investigational. It should not be described as an approved medicine or treated as interchangeable with online products bearing the same name.

RESEARCH AND MEDICAL NOTICE

This article is educational and does not provide medical advice, dosage recommendations, administration instructions, injection technique, reconstitution, storage, cycling, stacking or purchasing guidance. Administration levels appear only to explain named clinical trials. Weight and diabetes medicines can have important contraindications, interactions and monitoring requirements that need professional assessment.

RESEARCH LIBRARY

Sources

Primary evidenceFDA
FDA concerns with unapproved GLP-1 drugsOpen source →
Primary evidencenovonordisk-us.com
Novo Nordisk October 2026 regulatory updateOpen source →
Primary evidencePubMed
Kruse et al. Development of cagrilintide, a long-acting amylin analogueOpen source →
Primary evidencePubMed
Lau et al. Phase 2 cagrilintide monotherapy trialOpen source →
Primary evidencePubMed
Enebo et al. Phase 1b cagrilintide and semaglutide trialOpen source →
Primary evidencePubMed
Frias et al. Phase 2 CagriSema trial in type 2 diabetesOpen source →
Primary evidencePubMed
Garvey et al. REDEFINE 1 Phase 3 trialOpen source →
Primary evidencePubMed
Davies et al. REDEFINE 2 Phase 3 trialOpen source →
Primary evidencePubMed
Aroda et al. REIMAGINE 1 Phase 3 trialOpen source →
Primary evidencePubMed
Buse et al. REIMAGINE 2 Phase 3 trialOpen source →
Primary evidencePubMed
Rosenstock et al. REIMAGINE 3 Phase 3 trialOpen source →
Primary evidencePubMed
Verma et al. REDEFINE 1 blood-pressure analysisOpen source →
Primary evidencePubMed Central
Bower and Hay. Amylin structure and receptor biologyOpen source →
Primary evidenceDailyMed
DailyMed. SymlinPen pramlintide prescribing informationOpen source →
Primary evidenceNovo Nordisk
Novo Nordisk. CagriSema regulatory submission updateOpen source →
Primary evidenceNovo Nordisk
Novo Nordisk. September 2026 REIMAGINE 5 and REDEFINE 9 updateOpen source →
Primary evidenceNovo Nordisk
Novo Nordisk. Cagrilintide monotherapy developmentOpen source →
Primary evidenceEuropean Medicines Agency
European Medicines Agency. Cagrilintide and semaglutide paediatric plan recordOpen source →
Primary evidenceGoogle Patents
Patent describing manufacture of cagrilintide-related peptidesOpen source →

Research reviewed through 2 November 2026.